References
- HalpernRAgarwalSDembekCBortonLLopez-BresnahanMComparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysisPatient Prefer Adherence20115738421423591
- TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
- TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
- World Health Organization [webpage on the Internet]Adherence to Long-Term Therapies Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/index.htmlAccessed January 13, 2016
- BischoffCSchreiberHBergmannABackground information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environmentJ Neurol2012259112347235322527237
- VisserLHvan der ZandeAReasons patients give to use or not to use immunomodulating agents for multiple sclerosisEur J Neurol201118111343134921496180
- RiñonABuchMHolleyDVerdunEThe MS choices survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosisPatient Prefer Adherence2011562964322259240
- TorkildsenØMyhrKMBøLDisease-modifying treatments for multiple sclerosis – a review of approved medicationsEur J Neurol201623suppl 1182726563094
- PoulosCKinterEYangJCBridgesJFPosnerJRederATPatient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experimentPatient20169217118026259849
- PattiFOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherencePatient Prefer Adherence201041920165593
- LugaresiAZiemssenTOreja-GuevaraCThomasDVerdunEImproving patient-physician dialog: commentary on the results of the MS choices surveyPatient Prefer Adherence2012614315222379365